Archives of Dermatological Research

, Volume 277, Issue 4, pp 323–325 | Cite as

Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma

  • J. Keller
  • A. Kaltenecker
  • K. T. Schricker
  • B. Neidhardt
  • O. P. Hornstein
Short Communications

Key words

Platelet aggregation Raynaud's phenomenon Progressive systemic sclerosis Iloprost (ZK 36374) Intermittent infusion therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allen JA, O'Reilly MJ (1981) Treatment of severe Raynaud's phenomenon with prostaglandin E1. Ir J Med Sci 150:190–191Google Scholar
  2. 2.
    Baron M, Skrinskas G (1982) Prostaglandin-E1 therapy for digital ulcers in scleroderma. Can Med Assoc J 126:42–45Google Scholar
  3. 3.
    Belch JJF, Drury JK, Capell H (1983) Intermittent epoprostenerol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1:313–319Google Scholar
  4. 4.
    Breddin K, Grun H, Krywanek HJ, Schremmer WP (1975) Zur Messung der spontanen Thrombocytenaggregation. Plättchenaggregationstest. III. Methodik. Klin Wochenschr 53:81–87Google Scholar
  5. 5.
    Dowd PM, Kovacs IB (1981) Effects of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Br Med J [Clin Res] 283:350–354Google Scholar
  6. 6.
    Dowd PM, Martin MFR, Cooke ED, Bowcock S, Jones R, Dieppe PA, Kirby JD (1982) Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PG I2). Brit J Dermatol 106:81–89Google Scholar
  7. 7.
    Kahan A, Weber S, Amor B, Menkes CJ (1983) Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. Lancet 1:538Google Scholar
  8. 8.
    Kaukinen S, Pessi T, Ylitalo P, Krais T, Vapaatalo H (1984) Clinical study of ZK 36374 — a new stable prostacyclin analogue for treatment of peripheral vascular disease (ZK 36374 in peripheral vasculare disease). Progr Card Vasc Dis (in press)Google Scholar
  9. 9.
    Keller J, Kaltenecker A, Schricker KT, Krais T, Gevatter M, Hornstein OP (1984) Behandlung des Raynaud-Phänomens bei Sklerodermiepatienten mit einem neuen stabilen Prostacyclinderivat. Dtsch Med Wochenschr 109:1433–1438Google Scholar
  10. 10.
    Krais T (1982) Summary of the results of preclinical studies and phase-I trials with the prostacyclin analogue ZK 36374. Reprint Schering AG, BerlinGoogle Scholar
  11. 11.
    Martin MR, Dowd PM (1981) Prostaglandin-E1 infusion for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 40:350–354Google Scholar
  12. 12.
    Martin MF, Tooke JE (1982) Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis. Br med [Clin Res] 285:1688–1690Google Scholar
  13. 13.
    Silberbauer K, Sinzinger H, Punzengruber C (1982) Longterm prostacyclin (PGI2) therapy in peripheral arterial disease — influence in some vascular and platelet regulation mechanisms. Prostaglandins Clin Med Cardiovasc Thromb Dis 27:233–244Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • J. Keller
    • 1
  • A. Kaltenecker
    • 1
  • K. T. Schricker
    • 2
  • B. Neidhardt
    • 2
  • O. P. Hornstein
    • 1
  1. 1.Department of DermatologyUniversity of Erlangen-NürnbergErlangenGermany
  2. 2.Department of HematologyUniversity of Erlangen-NürnbergErlangenGermany

Personalised recommendations